Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
6696- DFC,  MET,    Combined Modulation of Tumor Metabolism by Metformin and Diclofenac in Glioma
- in-vitro, GBM, GBM
compI↓, Glycolysis↓, OCR↓, Glycolysis↑, lactateProd↓, eff↑, TumCP↓, TumCMig↓, TumCD∅,
6695- DFC,    Inhibition of lactate dehydrogenase A by diclofenac sodium induces apoptosis in HeLa cells through activation of AMPK
- in-vitro, Cerv, HeLa
other↝, Glycolysis↓, LDHA↓, Hypoxia↓, Apoptosis↑, lactateProd↓, ATP↓, mt-ROS↑, DNAdam↑, lipid-P↑, AMPK↑, p‑S6K↓, TumCP↓, Dose↝, selectivity↑, i-MDA↑, mtDam↑,
6694- DFC,    Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent
- Review, Var, NA
COX2/PTGS2↓, PGE2↓, angioG↓, ChemoSen↑, RadioS↑, Dose↝, toxicity↝, toxicity↝, BioAv↑, Half-Life↝, lactateProd↓, eff↑, *AntiAg↑,
6693- DFC,    New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells
- vitro+vivo, Var, NA
Myc↓, GLUT1↓, LDHA↓, MCT1↓, GlucoseCon↓, Glycolysis↓,
6692- DFC,    Diclofenac Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer by Modulation of VEGF Levels and Arginase Activity
- in-vivo, PC, Panc02
TumW↓, Apoptosis↑, VEGF↓, COX2/PTGS2↓, ARG1/2↑, TumCG↓, angioG↓, ARG↓, NO↓,
6691- DFC,    Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway
- in-vitro, Melanoma, NA - in-vitro, BC, MDA-MB-231 - in-vitro, BC, HCC1937 - in-vitro, BC, MCF7
Glycolysis↓, Apoptosis↑, cMyc↓, GLUT1↓, TumCP↓, HK2↓, TumCP↓,
6690- DFC,    Diclofenac: A Nonsteroidal Anti-Inflammatory Drug Inducing Cancer Cell Death by Inhibiting Microtubule Polymerization and Autophagy Flux
- in-vitro, Cerv, HeLa
Inflam↓, ROS↑, mitA↑, ChemoSen↑,
6689- DFC,    Diclofenac-Induced Apoptosis in the Neuroblastoma Cell Line SH-SY5Y: Possible Involvement of the Mitochondrial Superoxide Dismutase
- in-vitro, neuroblastoma, SH-SY5Y
Apoptosis↑, mtDam↑, ROS↑, SOD2↓, MMP↓, Cyt‑c↑, Dose↝, BBB↑,
6698- DFC,    Diclofenac induces proteasome and mitochondrial dysfunction in murine cardiomyocytes and hearts
- in-vivo, Nor, NA
*cardioP↓, *ROS↑, MMP↓, compIII↓,
6687- DFC,    Diclofenac-containing medicines - referral
- Review, Nor, NA
*Pain↓, *Inflam↓, *AntiArt↑, *cardioP↓,
1886- DFC,    Regulation of colonic epithelial butyrate transport: Focus on colorectal cancer
- Review, CRC, NA
SMCT1↑,
6666- DFE,    The impact of date palm fruits and their component polyphenols, on gut microbial ecology, bacterial metabolites and colon cancer cell proliferation
- in-vitro, Colon, Caco-2
*Fibre↑, *Poly↑, *other↝, *QC↑, *Api↑, *Myr↑, *LT↑, TumCP↓, *GutMicro↑, *Inflam↓, *antiOx↑,
6663- DFE,    Nutraceuticals of Phoenix dactylifera L.: Physicochemistry, Nutritional Value and Therapeutic Potential
- Review, Nor, NA - Review, AD, NA
*antiOx↑, *Inflam↓, *AntiBio↑, *AntiDiabetic↑, *AntiCan↑, *AntiArt↑, *neuroP↑, *hepatoP↑, *GastroP↑, *other↝, *cardioP↑, *cognitive↑, *ROS↓, *memory↑, *other↝, *SOD↑, *Catalase↑, *GSH↑, *GA↑, *Catechins↑, *FA↑, *QC↑, Api↑, *CA↑, *Imm↑, *Phen↑, *IL1β↓, *TGF-β↓, *COX1↓, *COX2/PTGS2↓, TumCP↓, Casp3↑, TumMeta↓, *GutMicro↑,
6664- DFE,    Anticancer Properties of Different Varieties of Date Palm (Phoenix dactylifera L.) Leaf Extracts in Human Tumor Cells: a Comparative Study
- in-vitro, BC, MDA-MB-231 - in-vitro, GBM, U87MG
TumCG↓, TumCMig↓, TumCI↓,
6665- DFE,    Cytotoxic Effect of Phoenix dactylifera (Iraqi Date) Leaves and Fruits Extracts against Breast Cancers Cell Lines
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, CAL51 - in-vitro, BC, MCF7
TumCD↑, eff↓, selectivity↑, AntiCan↑, TumCP↓, MMP↓, cl‑Casp3↑, cl‑PARP↑,
6667- DFE,    Immunostimulant effect of dates (Phoenix dactylifera) on humoral and cellular immunity cells and their functions
- in-vivo, Nor, NA
*Imm↑, *Inflam↓, *Flav↑,
6668- DFE,  AgNPs,    Saponin-Derived Silver Nanoparticles from Phoenix dactylifera (Ajwa Dates) Exhibit Broad-Spectrum Bioactivities Combating Bacterial Infections
- in-vitro, Lung, A549
*AntiBio↑, antiOx↑, TumCD↑, ROS↑, DNAdam↑, *Catalase↑, *GPx↑, *SOD↑, *ROS↓,
4456- DFE,    Induction of apoptosis and cell cycle arrest by ethyl acetate fraction of Phoenix dactylifera L. (Ajwa dates) in prostate cancer cells
- in-vitro, Pca, PC3
TumCD↑, MMP↓, mt-ROS↑, Apoptosis↑, TumCCA↑,
4455- DFE,    Ajwa Date (Phoenix dactylifera L.) Extract Inhibits Human Breast Adenocarcinoma (MCF7) Cells In Vitro by Inducing Apoptosis and Cell Cycle Arrest
- in-vitro, BC, MCF7 - in-vitro, Nor, 3T3
TumCCA↑, P53↑, BAX↑, Casp3↑, MMP↓, Fas↑, FasL↑, Bcl-2↓, Apoptosis↑, TumCP↓, TUNEL↑, eff↑, selectivity↑,
4454- DFE,    Cytostatic and Anti-tumor Potential of Ajwa Date Pulp against Human Hepatocellular Carcinoma HepG2 Cells
- in-vitro, Liver, HepG2
ROS↑, MMP↓, TumCCA↑, Apoptosis↑, selectivity↑, MMP↓, TumCCA↑,
7522- DFE,    Diet rich in date palm fruits improves memory, learning and reduces beta amyloid in transgenic mouse model of Alzheimer's disease
- in-vivo, AD, NA
*Aβ↓, *neuroP↑, *motorD↑, *memory↑, *Learn↑,
6745- DHA,    Omega-3 fatty acid DHA induces ferroptosis in colorectal cancer patient-derived organoids and drug-tolerant cells
- in-vitro, CRC, HT29
tumCV↓, selectivity↑, Ferroptosis↑, lipid-P↑, mt-ROS↑, ChemoSen↑, *toxicity↓, TumCG↓, eff↑, eff↑, Dose↝, mtDam↑, *Inflam↓, *chemoP↑, Dose↑,
6746- DHA,    Free docosahexaenoic acid promotes ferroptotic cell death via lipoxygenase dependent and independent pathways in cancer cells
- vitro+vivo, Pca, PC3 - in-vitro, Pca, 22Rv1 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP - in-vitro, Colon, HT29 - in-vitro, Cerv, HeLa
Ferroptosis↑, ROS↑, lipid-P↑,
6747- DHA,  erastin,    ELOVL5 Regulates Ferroptosis in Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
Ferroptosis↑, eff↑,
6748- DHA,    Docosahexaenoic acid enrichment of tumor phospholipid membranes increases tumor necroptosis in mice bearing triple negative breast cancer patient-derived xenografts
- in-vivo, BC, NA
TumCG↓, ChemoSen↑, NF-kB↓,
6749- DHA,    The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial
- Trial, BC, NA
*IFN-γ↑, *TNF-α↑, Imm↑,
6750- DHA,  Chemo,    Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial
- Trial, BC, NA
*CD14↑, *NLR↓, eff↑, *IL4↑, *IL10↑, *IFN-γ↑, *TNF-α↑, Imm↑, eff↑, TumW↓,
6751- DHA,    Exploratory outcomes of the DHA WIN randomized controlled trial: Supplementing women with docosahexaenoic acid did not reduce the impact of neoadjuvant breast cancer chemotherapy on quality of life or exercise behaviour
- Trial, BC, NA
QoL∅,
6752- DHA,    A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
- Trial, BC, NA
TNF-α∅, IL1β∅, COX2/PTGS2∅,
6753- DHA,    Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting (DHA-WIN)
ChemoSen↑, TumCG↓, Weight↑, chemoP↑, Dose↝,
6754- DHA,    Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial
- Trial, AD, NA
*DHA↑, *eff↝, *BrainVol∅, *cognitive∅,
6755- DHA,    Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia
- Trial, AD, NA
*other↝,
6756- DHA,    Omega-3 Fatty Acids and Cognitive Function
- Review, AD, NA
*cognitive↑, *memory↑, *eff↑,
6757- DHA,  EPA,    Does the ratio of eicosapentaenoic acid to docosahexaenoic acid matter in cancer treatment? A systematic review of their effects on cachexia-related inflammation
- Review, Var, NA
eff↝, Inflam↓, CRP↓,
6758- DHA,  Chemo,    Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial
- Trial, BC, NA
ChemoSen↑, selectivity↑, ROS↑, *toxicity↓, Dose↝,
6759- DHA,  doxoR,    Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7
ChemoSen↑, i-MDA↑, lipid-P↑, ROS↑,
6760- DHA,    Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans
- Trial, Nor, NA
*BP↓, *eff↝,
6761- DHA,    Docosahexaenoic acid reduces resting blood pressure but increases muscle sympathetic outflow compared with eicosapentaenoic acid in healthy men and women
- Trial, Nor, NA
*BP↓,
6762- DHA,  EPA,    Long-Chain Omega-3 Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid and Blood Pressure: A Meta-Analysis of Randomized Controlled Trials
- Review, Nor, NA
*Dose↝, *BP↓,
1184- DHA,    Syndecan-1-Dependent Suppression of PDK1/Akt/Bad Signaling by Docosahexaenoic Acid Induces Apoptosis in Prostate Cancer
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
SDC1↑, p‑PCK1↓, Akt↓, BAD↓,
1183- DHA,    Docosahexaenoic acid inhibited the Wnt/β-catenin pathway and suppressed breast cancer cells in vitro and in vivo
- in-vitro, BC, 4T1 - in-vitro, BC, MCF7 - in-vivo, BC, NA
TumCG↓, TumCCA↑, β-catenin/ZEB1↓, TCF↓, LEF1↓, cMyc↓, cycD1/CCND1↓, Wnt/(β-catenin)↓, TumMeta↓,
951- DHA,    Docosahexaenoic Acid Attenuates Breast Cancer Cell Metabolism and the Warburg Phenotype by Targeting Bioenergetic Function
- in-vitro, BC, BT474 - in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
Hif1a↓, GLUT1↓, LDH↓, GlucoseCon↓, lactateProd↓, ATP↓, p‑AMPK↑, ECAR↓, OCR↓, *toxicity↓,
1109- DHA,    DHA inhibits Gremlin-1-induced epithelial-to-mesenchymal transition via ERK suppression in human breast cancer cells
- in-vitro, BC, NA
GREM1↓, TumCMig↓, p‑ERK↓, EMT↓,
1085- DHA,  EPA,    DHA and EPA Down-regulate COX-2 Expression through Suppression of NF-kappaB Activity in LPS-treated Human Umbilical Vein Endothelial Cells
- in-vitro, Nor, HUVECs
*COX2/PTGS2↓, *NF-kB↓, *PGE2↓, *IL6↓, *NF-kB↑,
1035- DHA,    Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation
- vitro+vivo, NA, NA
PD-L1↓, FASN↓,
4178- DHA,    The salutary effects of DHA dietary supplementation on cognition, neuroplasticity, and membrane homeostasis after brain trauma
- in-vivo, NA, NA
*BDNF↑, *CREB↑, *cognitive↑, *SOD↑,
4177- DHA,    Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats
- in-vivo, NA, NA
*BDNF↑, *CREB↑, *ROS↓, *cognitive↑,
6722- DHCA,    Anticancer Properties of Phenolic Acids in Colon Cancer A Review
- Review, Colon, NA
TumCP↓,
6721- DHCA,    Dihydrocaffeic Acid—Is It the Less Known but Equally Valuable Phenolic Acid?
- Review, Nor, NA
*ROS↓, *Inflam↓, *eff↑, *other↝, *IL1β↓, *IL8↓, *TNF-α↓,
6719- DHCA,    Anticancer potential of dihydrocaffeic acid: a chlorogenic acid metabolite
- in-vitro, BC, MCF7 - in-vitro, Pca, PC3 - in-vitro, Liver, HepG2 - in-vitro, CRC, HCT116 - in-vitro, Nor, HDFa
*antiOx↑, *cardioP↑, *neuroP↑, selectivity↑, selectivity↓, TumCCA↑, ROS↑, mtDam↑,

Showing Research Papers: 3051 to 3100 of 8269
Prev Page 62 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ARG↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   compI↓, 1,   Ferroptosis↑, 3,   lipid-P↑, 4,   i-MDA↑, 2,   ROS↑, 8,   mt-ROS↑, 3,   SOD2↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 2,   compIII↓, 1,   MMP↓, 7,   mtDam↑, 4,   OCR↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   p‑AMPK↑, 1,   cMyc↓, 2,   ECAR↓, 1,   FASN↓, 1,   GlucoseCon↓, 2,   Glycolysis↓, 4,   Glycolysis↑, 1,   HK2↓, 1,   lactateProd↓, 4,   LDH↓, 1,   LDHA↓, 2,   p‑PCK1↓, 1,   p‑S6K↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 7,   BAD↓, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 2,   cl‑Casp3↑, 1,   Cyt‑c↑, 1,   Fas↑, 1,   FasL↑, 1,   Ferroptosis↑, 3,   MCT1↓, 1,   Myc↓, 1,   TumCD↑, 3,   TumCD∅, 1,   TUNEL↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,   tumCV↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 2,   P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   mitA↑, 1,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,   p‑ERK↓, 1,   GREM1↓, 1,   TCF↓, 1,   TumCG↓, 6,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

ARG1/2↑, 1,   LEF1↓, 1,   SDC1↑, 1,   TumCI↓, 1,   TumCMig↓, 3,   TumCP↓, 9,   TumMeta↓, 2,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   Hif1a↓, 1,   Hypoxia↓, 1,   NO↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   GLUT1↓, 3,   SMCT1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   COX2/PTGS2∅, 1,   CRP↓, 1,   IL1β∅, 1,   Imm↑, 2,   Inflam↓, 2,   NF-kB↓, 1,   PD-L1↓, 1,   PGE2↓, 1,   TNF-α∅, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   ChemoSen↑, 7,   Dose↑, 1,   Dose↝, 6,   eff↓, 1,   eff↑, 8,   eff↝, 1,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↓, 1,   selectivity↑, 7,  

Clinical Biomarkers(tgid=22) ⓘ

CRP↓, 1,   LDH↓, 1,   Myc↓, 1,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   chemoP↑, 1,   QoL∅, 1,   toxicity↝, 2,   TumW↓, 2,   Weight↑, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Api↑, 1,  
Total Targets: 106

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiArt↑, 2,   AntiBio↑, 2,   Learn↑, 1,   NLR↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   Catalase↑, 2,   GPx↑, 1,   GSH↑, 1,   ROS↓, 4,   ROS↑, 1,   SOD↑, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

CREB↑, 2,   DHA↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 5,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   TGF-β↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GastroP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD14↑, 1,   COX1↓, 1,   COX2/PTGS2↓, 2,   IFN-γ↑, 2,   IL10↑, 1,   IL1β↓, 2,   IL4↑, 1,   IL6↓, 1,   IL8↓, 1,   Imm↑, 2,   Inflam↓, 6,   NF-kB↓, 1,   NF-kB↑, 1,   PGE2↓, 1,   TNF-α↓, 1,   TNF-α↑, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF↑, 2,   BrainVol∅, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   eff↑, 2,   eff↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

BP↓, 3,   GutMicro↑, 2,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiDiabetic↑, 1,   cardioP↓, 2,   cardioP↑, 2,   chemoP↑, 1,   cognitive↑, 4,   cognitive∅, 1,   hepatoP↑, 1,   memory↑, 3,   motorD↑, 1,   neuroP↑, 3,   Pain↓, 1,   toxicity↓, 3,  

Ingredients & Constituents(tgid=25) ⓘ

Api↑, 1,   CA↑, 1,   Catechins↑, 1,   FA↑, 1,   Fibre↑, 1,   Flav↑, 1,   GA↑, 1,   LT↑, 1,   Myr↑, 1,   Phen↑, 1,   Poly↑, 1,   QC↑, 2,  
Total Targets: 67

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page